{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:55:56Z","timestamp":1792742156325,"version":"4.5.0"},"reference-count":148,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"DOI":"10.1007\/s40618-025-02767-2","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T09:00:54Z","timestamp":1764752454000},"page":"747-761","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Hormonal crossroads of the heart: from classic endocrine regulation to cardiac hormone secretion: an updated review"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0126-1985","authenticated-orcid":false,"given":"Pedro","family":"Iglesias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e9s","family":"Iglesias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"key":"2767_CR1","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.mcna.2012.01.006","volume":"96","author":"S Danzi","year":"2012","unstructured":"Danzi S, Klein I (2012) Thyroid hormone and the cardiovascular system. Med Clin North Am 96:257\u2013268. https:\/\/doi.org\/10.1016\/j.mcna.2012.01.006","journal-title":"Med Clin North Am"},{"key":"2767_CR2","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s11102-020-01036-0","volume":"23","author":"S Zhang","year":"2020","unstructured":"Zhang S, Li Z, Lv Y et al (2020) Cardiovascular effects of growth hormone (GH) treatment on GH-deficient adults: a meta-analysis update. Pituitary 23:467\u2013475. https:\/\/doi.org\/10.1007\/s11102-020-01036-0","journal-title":"Pituitary"},{"key":"2767_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14061906","volume":"14","author":"P Iglesias","year":"2025","unstructured":"Iglesias P (2025) Acromegaly and cardiovascular disease: associated cardiovascular risk factors, cardiovascular prognosis, and therapeutic impact. J Clin Med 14:1906. https:\/\/doi.org\/10.3390\/jcm14061906","journal-title":"J Clin Med"},{"key":"2767_CR4","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s11897-012-0107-7","volume":"9","author":"SM Dunlay","year":"2012","unstructured":"Dunlay SM, Roger VL (2012) Gender differences in the pathophysiology, clinical presentation, and outcomes of ischemic heart failure. Curr Heart Fail Rep 9:267\u2013276. https:\/\/doi.org\/10.1007\/s11897-012-0107-7","journal-title":"Curr Heart Fail Rep"},{"key":"2767_CR5","doi-asserted-by":"publisher","first-page":"157","DOI":"10.36628\/ijhf.2020.0004","volume":"2","author":"V Regitz-Zagrosek","year":"2020","unstructured":"Regitz-Zagrosek V (2020) Sex and gender differences in heart failure. Int J Heart Fail 2:157\u2013181. https:\/\/doi.org\/10.36628\/ijhf.2020.0004","journal-title":"Int J Heart Fail"},{"key":"2767_CR6","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1161\/01.CIR.0000140766.52771.6D","volume":"110","author":"F-P Xu","year":"2004","unstructured":"Xu F-P, Chen M-S, Wang Y-Z et al (2004) Leptin induces hypertrophy via endothelin-1-reactive oxygen species pathway in cultured neonatal rat cardiomyocytes. Circulation 110:1269\u20131275. https:\/\/doi.org\/10.1161\/01.CIR.0000140766.52771.6D","journal-title":"Circulation"},{"key":"2767_CR7","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1253\/circj.cj-09-0057","volume":"73","author":"R Shibata","year":"2009","unstructured":"Shibata R, Ouchi N, Murohara T (2009) Adiponectin and cardiovascular disease. Circ J 73:608\u2013614. https:\/\/doi.org\/10.1253\/circj.cj-09-0057","journal-title":"Circ J"},{"key":"2767_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25158369","volume":"25","author":"A Caturano","year":"2024","unstructured":"Caturano A, Galiero R, Vetrano E et al (2024) Insulin-heart axis: bridging physiology to insulin resistance. Int J Mol Sci 25:8369. https:\/\/doi.org\/10.3390\/ijms25158369","journal-title":"Int J Mol Sci"},{"key":"2767_CR9","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.arteri.2014.07.003","volume":"26","author":"H Vargas-Uricoechea","year":"2014","unstructured":"Vargas-Uricoechea H, Bonelo-Perdomo A, Sierra-Torres CH (2014) Effects of thyroid hormones on the heart. Clin Investig Arterioscler 26:296\u2013309. https:\/\/doi.org\/10.1016\/j.arteri.2014.07.003","journal-title":"Clin Investig Arterioscler"},{"key":"2767_CR10","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s11102-005-1172-7","volume":"7","author":"G Arnaldi","year":"2004","unstructured":"Arnaldi G, Mancini T, Polenta B, Boscaro M (2004) Cardiovascular risk in Cushing\u2019s syndrome. Pituitary 7:253\u2013256. https:\/\/doi.org\/10.1007\/s11102-005-1172-7","journal-title":"Pituitary"},{"key":"2767_CR11","doi-asserted-by":"publisher","first-page":"153","DOI":"10.2174\/1570161115666171010115119","volume":"17","author":"MA Abdul-Ghani","year":"2019","unstructured":"Abdul-Ghani MA, Jayyousi A, DeFronzo RA et al (2019) Insulin resistance the link between T2DM and CVD: basic mechanisms and clinical implications. Curr Vasc Pharmacol 17:153\u2013163. https:\/\/doi.org\/10.2174\/1570161115666171010115119","journal-title":"Curr Vasc Pharmacol"},{"key":"2767_CR12","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1056\/NEJMoa020245","volume":"347","author":"S Kenchaiah","year":"2002","unstructured":"Kenchaiah S, Evans JC, Levy D et al (2002) Obesity and the risk of heart failure. N Engl J Med 347:305\u2013313. https:\/\/doi.org\/10.1056\/NEJMoa020245","journal-title":"N Engl J Med"},{"key":"2767_CR13","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1161\/01.cir.96.2.526","volume":"96","author":"SD Anker","year":"1997","unstructured":"Anker SD, Chua TP, Ponikowski P et al (1997) Hormonal changes and catabolic\/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 96:526\u2013534. https:\/\/doi.org\/10.1161\/01.cir.96.2.526","journal-title":"Circulation"},{"key":"2767_CR14","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1055\/s-0029-1224182","volume":"41","author":"EV Sivukhina","year":"2009","unstructured":"Sivukhina EV, Poskrebysheva AS, Smurova IV et al (2009) Altered hypothalamic-pituitary-adrenal axis activity in patients with chronic heart failure. Horm Metab Res 41:778\u2013784. https:\/\/doi.org\/10.1055\/s-0029-1224182","journal-title":"Horm Metab Res"},{"key":"2767_CR15","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1161\/01.cir.0000048124.64204.3f","volume":"107","author":"G Iervasi","year":"2003","unstructured":"Iervasi G, Pingitore A, Landi P et al (2003) Low-T3 syndrome: a strong prognostic predictor of death in patients with heart disease. Circulation 107:708\u2013713. https:\/\/doi.org\/10.1161\/01.cir.0000048124.64204.3f","journal-title":"Circulation"},{"key":"2767_CR16","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.jacc.2005.02.093","volume":"46","author":"W Doehner","year":"2005","unstructured":"Doehner W, Rauchhaus M, Ponikowski P et al (2005) Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. J Am Coll Cardiol 46:1019\u20131026. https:\/\/doi.org\/10.1016\/j.jacc.2005.02.093","journal-title":"J Am Coll Cardiol"},{"key":"2767_CR17","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1007\/s12020-021-02912-w","volume":"75","author":"G Lisco","year":"2022","unstructured":"Lisco G, Giagulli VA, Iovino M et al (2022) Endocrine system dysfunction and chronic heart failure: a clinical perspective. Endocrine 75:360\u2013376. https:\/\/doi.org\/10.1007\/s12020-021-02912-w","journal-title":"Endocrine"},{"key":"2767_CR18","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/nrurol.2018.20","volume":"15","author":"F Lotti","year":"2018","unstructured":"Lotti F, Maggi M (2018) Sexual dysfunction and male infertility. Nat Rev Urol 15:287\u2013307. https:\/\/doi.org\/10.1038\/nrurol.2018.20","journal-title":"Nat Rev Urol"},{"key":"2767_CR19","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1007\/s11914-012-0115-2","volume":"10","author":"AO Aluoch","year":"2012","unstructured":"Aluoch AO, Jessee R, Habal H et al (2012) Heart failure as a risk factor for osteoporosis and fractures. Curr Osteoporos Rep 10:258\u2013269. https:\/\/doi.org\/10.1007\/s11914-012-0115-2","journal-title":"Curr Osteoporos Rep"},{"key":"2767_CR20","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJM199807303390507","volume":"339","author":"ER Levin","year":"1998","unstructured":"Levin ER, Gardner DG, Samson WK (1998) Natriuretic peptides. N Engl J Med 339:321\u2013328. https:\/\/doi.org\/10.1056\/NEJM199807303390507","journal-title":"N Engl J Med"},{"key":"2767_CR21","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/s41569-020-0381-0","volume":"17","author":"JP Goetze","year":"2020","unstructured":"Goetze JP, Bruneau BG, Ramos HR et al (2020) Cardiac natriuretic peptides. Nat Rev Cardiol 17:698\u2013717. https:\/\/doi.org\/10.1038\/s41569-020-0381-0","journal-title":"Nat Rev Cardiol"},{"key":"2767_CR22","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/bs.apcsb.2017.01.002","volume":"108","author":"A Planavila","year":"2017","unstructured":"Planavila A, Fern\u00e1ndez-Sol\u00e0 J, Villarroya F (2017) Cardiokines as modulators of stress-induced cardiac disorders. Adv Protein Chem Struct Biol 108:227\u2013256. https:\/\/doi.org\/10.1016\/bs.apcsb.2017.01.002","journal-title":"Adv Protein Chem Struct Biol"},{"key":"2767_CR23","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1007\/s00018-017-2723-6","volume":"75","author":"A Chiba","year":"2018","unstructured":"Chiba A, Watanabe-Takano H, Miyazaki T, Mochizuki N (2018) Cardiomyokines from the heart. Cell Mol Life Sci 75:1349\u20131362. https:\/\/doi.org\/10.1007\/s00018-017-2723-6","journal-title":"Cell Mol Life Sci"},{"key":"2767_CR24","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1161\/CIRCULATIONAHA.106.678326","volume":"116","author":"I Klein","year":"2007","unstructured":"Klein I, Danzi S (2007) Thyroid disease and the heart. Circulation 116:1725\u20131735. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.678326","journal-title":"Circulation"},{"key":"2767_CR25","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1530\/EJE-07-0455","volume":"157","author":"BR Walker","year":"2007","unstructured":"Walker BR (2007) Glucocorticoids and cardiovascular disease. Eur J Endocrinol 157:545\u2013559. https:\/\/doi.org\/10.1530\/EJE-07-0455","journal-title":"Eur J Endocrinol"},{"key":"2767_CR26","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1161\/CIRCRESAHA.116.308999","volume":"118","author":"PE Scherer","year":"2016","unstructured":"Scherer PE, Hill JA (2016) Obesity, diabetes, and cardiovascular diseases: a compendium. Circ Res 118:1703\u20131705. https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.308999","journal-title":"Circ Res"},{"key":"2767_CR27","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.hfc.2019.03.001","volume":"15","author":"A Colao","year":"2019","unstructured":"Colao A, Grasso LFS, Di Somma C, Pivonello R (2019) Acromegaly and heart failure. Heart Fail Clin 15:399\u2013408. https:\/\/doi.org\/10.1016\/j.hfc.2019.03.001","journal-title":"Heart Fail Clin"},{"key":"2767_CR28","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/0024-3205(81)90370-2","volume":"28","author":"AJ de Bold","year":"1981","unstructured":"de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H (1981) A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 28:89\u201394. https:\/\/doi.org\/10.1016\/0024-3205(81)90370-2","journal-title":"Life Sci"},{"key":"2767_CR29","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.1161\/01.CIR.0000100720.01867.1D","volume":"108","author":"P Maison","year":"2003","unstructured":"Maison P, Chanson P (2003) Cardiac effects of growth hormone in adults with growth hormone deficiency: a meta-analysis. Circulation 108:2648\u20132652. https:\/\/doi.org\/10.1161\/01.CIR.0000100720.01867.1D","journal-title":"Circulation"},{"key":"2767_CR30","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.cell.2006.12.036","volume":"128","author":"D Hilfiker-Kleiner","year":"2007","unstructured":"Hilfiker-Kleiner D, Kaminski K, Podewski E et al (2007) A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 128:589\u2013600. https:\/\/doi.org\/10.1016\/j.cell.2006.12.036","journal-title":"Cell"},{"key":"2767_CR31","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1038\/nrcardio.2014.37","volume":"11","author":"D Hilfiker-Kleiner","year":"2014","unstructured":"Hilfiker-Kleiner D, Sliwa K (2014) Pathophysiology and epidemiology of peripartum cardiomyopathy. Nat Rev Cardiol 11:364\u2013370. https:\/\/doi.org\/10.1038\/nrcardio.2014.37","journal-title":"Nat Rev Cardiol"},{"key":"2767_CR32","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1056\/NEJMra2306667","volume":"390","author":"Z Arany","year":"2024","unstructured":"Arany Z (2024) Peripartum cardiomyopathy. N Engl J Med 390:154\u2013164. https:\/\/doi.org\/10.1056\/NEJMra2306667","journal-title":"N Engl J Med"},{"key":"2767_CR33","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1016\/j.jacc.2005.02.095","volume":"46","author":"SR Goldsmith","year":"2005","unstructured":"Goldsmith SR, Gheorghiade M (2005) Vasopressin antagonism in heart failure. J Am Coll Cardiol 46:1785\u20131791. https:\/\/doi.org\/10.1016\/j.jacc.2005.02.095","journal-title":"J Am Coll Cardiol"},{"key":"2767_CR34","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1001\/jama.297.12.1332","volume":"297","author":"M Gheorghiade","year":"2007","unstructured":"Gheorghiade M, Konstam MA, Burnett JC et al (2007) Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 297:1332\u20131343. https:\/\/doi.org\/10.1001\/jama.297.12.1332","journal-title":"JAMA"},{"key":"2767_CR35","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1161\/01.hyp.38.2.292","volume":"38","author":"S Mukaddam-Daher","year":"2001","unstructured":"Mukaddam-Daher S, Yin YL, Roy J et al (2001) Negative inotropic and chronotropic effects of oxytocin. Hypertension 38:292\u2013296. https:\/\/doi.org\/10.1161\/01.hyp.38.2.292","journal-title":"Hypertension"},{"key":"2767_CR36","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.3389\/fpsyg.2020.02139","volume":"11","author":"M Jankowski","year":"2020","unstructured":"Jankowski M, Broderick TL, Gutkowska J (2020) The role of oxytocin in cardiovascular protection. Front Psychol 11:2139. https:\/\/doi.org\/10.3389\/fpsyg.2020.02139","journal-title":"Front Psychol"},{"key":"2767_CR37","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1089\/105072502760143845","volume":"12","author":"GJ Kahaly","year":"2002","unstructured":"Kahaly GJ, Kampmann C, Mohr-Kahaly S (2002) Cardiovascular hemodynamics and exercise tolerance in thyroid disease. Thyroid 12:473\u2013481. https:\/\/doi.org\/10.1089\/105072502760143845","journal-title":"Thyroid"},{"key":"2767_CR38","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1210\/er.2003-0033","volume":"26","author":"GJ Kahaly","year":"2005","unstructured":"Kahaly GJ, Dillmann WH (2005) Thyroid hormone action in the heart. Endocr Rev 26:704\u2013728. https:\/\/doi.org\/10.1210\/er.2003-0033","journal-title":"Endocr Rev"},{"key":"2767_CR39","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1210\/jc.2007-2210","volume":"93","author":"A Pingitore","year":"2008","unstructured":"Pingitore A, Galli E, Barison A et al (2008) Acute effects of triiodothyronine (T3) replacement therapy in patients with chronic heart failure and low-T3 syndrome: a randomized, placebo-controlled study. J Clin Endocrinol Metab 93:1351\u20131358. https:\/\/doi.org\/10.1210\/jc.2007-2210","journal-title":"J Clin Endocrinol Metab"},{"key":"2767_CR40","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/j.eprac.2022.07.004","volume":"28","author":"C Shi","year":"2022","unstructured":"Shi C, Bao Y, Chen X, Tian L (2022) The effectiveness of thyroid hormone replacement therapy on heart failure and low-triiodothyronine syndrome: an updated systematic review and meta-analysis of randomized controlled trials. Endocr Pract 28:1178\u20131186. https:\/\/doi.org\/10.1016\/j.eprac.2022.07.004","journal-title":"Endocr Pract"},{"key":"2767_CR41","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1089\/thy.2021.0609","volume":"32","author":"M Tharmapoopathy","year":"2022","unstructured":"Tharmapoopathy M, Thavarajah A, Kenny RPW et al (2022) Efficacy and safety of triiodothyronine treatment in cardiac surgery or cardiovascular diseases: a systematic review and meta-analysis of randomized controlled trials. Thyroid 32:879\u2013896. https:\/\/doi.org\/10.1089\/thy.2021.0609","journal-title":"Thyroid"},{"key":"2767_CR42","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1089\/thy.2022.0717","volume":"33","author":"JS Neves","year":"2023","unstructured":"Neves JS, Leite AR, Concei\u00e7\u00e3o G et al (2023) Effects of triiodothyronine treatment in an animal model of heart failure with preserved ejection fraction. Thyroid 33:983\u2013996. https:\/\/doi.org\/10.1089\/thy.2022.0717","journal-title":"Thyroid"},{"key":"2767_CR43","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1089\/thy.2014.0028","volume":"24","author":"J Jonklaas","year":"2014","unstructured":"Jonklaas J, Bianco AC, Bauer AJ et al (2014) Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association task force on thyroid hormone replacement. Thyroid 24:1670\u20131751. https:\/\/doi.org\/10.1089\/thy.2014.0028","journal-title":"Thyroid"},{"key":"2767_CR44","doi-asserted-by":"publisher","first-page":"e579","DOI":"10.1161\/CIR.0000000000000455","volume":"134","author":"B Bozkurt","year":"2016","unstructured":"Bozkurt B, Colvin M, Cook J et al (2016) Current diagnostic and treatment strategies for specific dilated cardiomyopathies: a scientific statement from the American Heart Association. Circulation 134:e579\u2013e646. https:\/\/doi.org\/10.1161\/CIR.0000000000000455","journal-title":"Circulation"},{"key":"2767_CR45","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/s0008-6363(97)00194-6","volume":"37","author":"KD Schl\u00fcter","year":"1998","unstructured":"Schl\u00fcter KD, Piper HM (1998) Cardiovascular actions of parathyroid hormone and parathyroid hormone-related peptide. Cardiovasc Res 37:34\u201341. https:\/\/doi.org\/10.1016\/s0008-6363(97)00194-6","journal-title":"Cardiovasc Res"},{"key":"2767_CR46","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1056\/NEJM200012213432508","volume":"343","author":"SJ Marx","year":"2000","unstructured":"Marx SJ (2000) Hyperparathyroid and hypoparathyroid disorders. N Engl J Med 343:1863\u20131875. https:\/\/doi.org\/10.1056\/NEJM200012213432508","journal-title":"N Engl J Med"},{"key":"2767_CR47","doi-asserted-by":"publisher","first-page":"5628","DOI":"10.2174\/1381612824999201105165642","volume":"26","author":"S Tournis","year":"2020","unstructured":"Tournis S, Makris K, Cavalier E, Trovas G (2020) Cardiovascular risk in patients with primary hyperparathyroidism. Curr Pharm Des 26:5628\u20135636. https:\/\/doi.org\/10.2174\/1381612824999201105165642","journal-title":"Curr Pharm Des"},{"key":"2767_CR48","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s40618-016-0561-2","volume":"40","author":"G Loncar","year":"2017","unstructured":"Loncar G, Bozic B, Cvetinovic N et al (2017) Secondary hyperparathyroidism prevalence and prognostic role in elderly males with heart failure. J Endocrinol Invest 40:297\u2013304. https:\/\/doi.org\/10.1007\/s40618-016-0561-2","journal-title":"J Endocrinol Invest"},{"key":"2767_CR49","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s10741-012-9336-9","volume":"18","author":"S Gandhi","year":"2013","unstructured":"Gandhi S, Myers RBH (2013) Can parathyroid hormone be used as a biomarker for heart failure? Heart Fail Rev 18:465\u2013473. https:\/\/doi.org\/10.1007\/s10741-012-9336-9","journal-title":"Heart Fail Rev"},{"key":"2767_CR50","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.metabol.2013.08.016","volume":"63","author":"A Tomaschitz","year":"2014","unstructured":"Tomaschitz A, Ritz E, Pieske B et al (2014) Aldosterone and parathyroid hormone interactions as mediators of metabolic and cardiovascular disease. Metabolism 63:20\u201331. https:\/\/doi.org\/10.1016\/j.metabol.2013.08.016","journal-title":"Metabolism"},{"key":"2767_CR51","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.medcli.2013.02.039","volume":"141","author":"J Casado Cerrada","year":"2013","unstructured":"Casado Cerrada J, Parra Caballero P, Vega Piris L, Su\u00e1rez Fern\u00e1ndez C (2013) Relation between parathyroid hormone and cardiovascular risk in patients with vitamin D deficiency. Med Clin (Barc) 141:292\u2013294. https:\/\/doi.org\/10.1016\/j.medcli.2013.02.039","journal-title":"Med Clin (Barc)"},{"key":"2767_CR52","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.3390\/nu14153009","volume":"14","author":"V Brandenburg","year":"2022","unstructured":"Brandenburg V, Ketteler M (2022) Vitamin D and secondary hyperparathyroidism in chronic kidney disease: a critical appraisal of the past, present, and the future. Nutrients 14:3009. https:\/\/doi.org\/10.3390\/nu14153009","journal-title":"Nutrients"},{"key":"2767_CR53","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1210\/jc.2002-021558","volume":"88","author":"A Faggiano","year":"2003","unstructured":"Faggiano A, Pivonello R, Spiezia S et al (2003) Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing\u2019s disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab 88:2527\u20132533. https:\/\/doi.org\/10.1210\/jc.2002-021558","journal-title":"J Clin Endocrinol Metab"},{"key":"2767_CR54","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S2213-8587(14)70142-1","volume":"3","author":"I Bancos","year":"2015","unstructured":"Bancos I, Hahner S, Tomlinson J, Arlt W (2015) Diagnosis and management of adrenal insufficiency. Lancet Diabetes Endocrinol 3:216\u2013226. https:\/\/doi.org\/10.1016\/S2213-8587(14)70142-1","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2767_CR55","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41572-021-00252-7","volume":"7","author":"S Hahner","year":"2021","unstructured":"Hahner S, Ross RJ, Arlt W et al (2021) Adrenal insufficiency. Nat Rev Dis Primers 7:19. https:\/\/doi.org\/10.1038\/s41572-021-00252-7","journal-title":"Nat Rev Dis Primers"},{"key":"2767_CR56","first-page":"893","volume":"120","author":"CG Brilla","year":"1992","unstructured":"Brilla CG, Weber KT (1992) Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med 120:893\u2013901","journal-title":"J Lab Clin Med"},{"key":"2767_CR57","doi-asserted-by":"publisher","first-page":"H1802","DOI":"10.1152\/ajpheart.01096.2001","volume":"283","author":"R Rocha","year":"2002","unstructured":"Rocha R, Rudolph AE, Frierdich GE et al (2002) Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 283:H1802-1810. https:\/\/doi.org\/10.1152\/ajpheart.01096.2001","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2767_CR58","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ et al (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709\u2013717. https:\/\/doi.org\/10.1056\/NEJM199909023411001","journal-title":"N Engl J Med"},{"key":"2767_CR59","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F et al (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309\u20131321. https:\/\/doi.org\/10.1056\/NEJMoa030207","journal-title":"N Engl J Med"},{"key":"2767_CR60","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad F, McMurray JJV, Krum H et al (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364:11\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1009492","journal-title":"N Engl J Med"},{"key":"2767_CR61","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1139\/y09-042","volume":"87","author":"A Adameova","year":"2009","unstructured":"Adameova A, Abdellatif Y, Dhalla NS (2009) Role of the excessive amounts of circulating catecholamines and glucocorticoids in stress-induced heart disease. Can J Physiol Pharmacol 87:493\u2013514. https:\/\/doi.org\/10.1139\/y09-042","journal-title":"Can J Physiol Pharmacol"},{"key":"2767_CR62","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/ejhf.2400","volume":"24","author":"E Omerovic","year":"2022","unstructured":"Omerovic E, Citro R, Bossone E et al (2022) Pathophysiology of Takotsubo syndrome\u00a0-\u00a0a joint scientific statement from the Heart Failure Association Takotsubo Syndrome Study Group and Myocardial Function Working Group of the European Society of Cardiology\u00a0-\u00a0part 1: overview and the central role for catecholamines and sympathetic nervous system. Eur J Heart Fail 24:257\u2013273. https:\/\/doi.org\/10.1002\/ejhf.2400","journal-title":"Eur J Heart Fail"},{"key":"2767_CR63","doi-asserted-by":"publisher","first-page":"4405","DOI":"10.3390\/jcm11154405","volume":"11","author":"MY Henein","year":"2022","unstructured":"Henein MY, Vancheri S, Longo G, Vancheri F (2022) The impact of mental stress on cardiovascular health-Part II. J Clin Med 11:4405. https:\/\/doi.org\/10.3390\/jcm11154405","journal-title":"J Clin Med"},{"key":"2767_CR64","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1056\/NEJM199908193410806","volume":"341","author":"RW Schrier","year":"1999","unstructured":"Schrier RW, Abraham WT (1999) Hormones and hemodynamics in heart failure. N Engl J Med 341:577\u2013585. https:\/\/doi.org\/10.1056\/NEJM199908193410806","journal-title":"N Engl J Med"},{"key":"2767_CR65","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1093\/eurheartj\/ehac759","volume":"44","author":"M Volpe","year":"2023","unstructured":"Volpe M, Gallo G, Rubattu S (2023) Endocrine functions of the heart: from bench to bedside. Eur Heart J 44:643\u2013655. https:\/\/doi.org\/10.1093\/eurheartj\/ehac759","journal-title":"Eur Heart J"},{"key":"2767_CR66","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.pharmthera.2003.11.001","volume":"101","author":"SP D\u2019Souza","year":"2004","unstructured":"D\u2019Souza SP, Davis M, Baxter GF (2004) Autocrine and paracrine actions of natriuretic peptides in the heart. Pharmacol Ther 101:113\u2013129. https:\/\/doi.org\/10.1016\/j.pharmthera.2003.11.001","journal-title":"Pharmacol Ther"},{"key":"2767_CR67","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1161\/HYPERTENSIONAHA.114.05054","volume":"66","author":"D Li","year":"2015","unstructured":"Li D, Lu C-J, Hao G et al (2015) Efficacy of B-type natriuretic peptide is coupled to phosphodiesterase 2A in cardiac sympathetic neurons. Hypertension 66:190\u2013198. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.114.05054","journal-title":"Hypertension"},{"key":"2767_CR68","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1056\/NEJM199906103402306","volume":"340","author":"ME Mendelsohn","year":"1999","unstructured":"Mendelsohn ME, Karas RH (1999) The protective effects of estrogen on the cardiovascular system. N Engl J Med 340:1801\u20131811. https:\/\/doi.org\/10.1056\/NEJM199906103402306","journal-title":"N Engl J Med"},{"key":"2767_CR69","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1161\/CIRCRESAHA.110.236687","volume":"109","author":"E Murphy","year":"2011","unstructured":"Murphy E (2011) Estrogen signaling and cardiovascular disease. Circ Res 109:687\u2013696. https:\/\/doi.org\/10.1161\/CIRCRESAHA.110.236687","journal-title":"Circ Res"},{"key":"2767_CR70","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.jacc.2011.03.042","volume":"58","author":"CSP Lam","year":"2011","unstructured":"Lam CSP, Cheng S, Choong K et al (2011) Influence of sex and hormone status on circulating natriuretic peptides. J Am Coll Cardiol 58:618\u2013626. https:\/\/doi.org\/10.1016\/j.jacc.2011.03.042","journal-title":"J Am Coll Cardiol"},{"key":"2767_CR71","doi-asserted-by":"publisher","first-page":"458","DOI":"10.5114\/aoms\/157308","volume":"19","author":"K Ryczkowska","year":"2023","unstructured":"Ryczkowska K, Adach W, Janikowski K et al (2023) Menopause and women\u2019s cardiovascular health: is it really an obvious relationship? Arch Med Sci 19:458\u2013466. https:\/\/doi.org\/10.5114\/aoms\/157308","journal-title":"Arch Med Sci"},{"key":"2767_CR72","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1093\/cvr\/cvaf086","volume":"121","author":"C Fontaine","year":"2025","unstructured":"Fontaine C, Gosset A, Davezac M et al (2025) From sex hormone decrease to hormonal treatment: impacts on cardiovascular risk with ageing. Cardiovasc Res 121:1551\u20131565. https:\/\/doi.org\/10.1093\/cvr\/cvaf086","journal-title":"Cardiovasc Res"},{"key":"2767_CR73","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1161\/CIR.0000000000000381","volume":"133","author":"JC McSweeney","year":"2016","unstructured":"McSweeney JC, Rosenfeld AG, Abel WM et al (2016) Preventing and experiencing ischemic heart disease as a woman: state of the science: a scientific statement from the American Heart Association. Circulation 133:1302\u20131331. https:\/\/doi.org\/10.1161\/CIR.0000000000000381","journal-title":"Circulation"},{"key":"2767_CR74","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1136\/hrt.2003.014639","volume":"90","author":"PJ Pugh","year":"2004","unstructured":"Pugh PJ, Jones RD, West JN et al (2004) Testosterone treatment for men with chronic heart failure. Heart 90:446\u2013447. https:\/\/doi.org\/10.1136\/hrt.2003.014639","journal-title":"Heart"},{"key":"2767_CR75","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.jacc.2015.12.005","volume":"67","author":"RA Kloner","year":"2016","unstructured":"Kloner RA, Carson C, Dobs A et al (2016) Testosterone and cardiovascular disease. J Am Coll Cardiol 67:545\u2013557. https:\/\/doi.org\/10.1016\/j.jacc.2015.12.005","journal-title":"J Am Coll Cardiol"},{"key":"2767_CR76","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1517\/14740338.2014.950653","volume":"13","author":"G Corona","year":"2014","unstructured":"Corona G, Maseroli E, Rastrelli G et al (2014) Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. Expert Opin Drug Saf 13:1327\u20131351. https:\/\/doi.org\/10.1517\/14740338.2014.950653","journal-title":"Expert Opin Drug Saf"},{"key":"2767_CR77","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1161\/CIRCHEARTFAILURE.111.965632","volume":"5","author":"M Toma","year":"2012","unstructured":"Toma M, McAlister FA, Coglianese EE et al (2012) Testosterone supplementation in heart failure: a meta-analysis. Circ Heart Fail 5:315\u2013321. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.111.965632","journal-title":"Circ Heart Fail"},{"key":"2767_CR78","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1249\/MSS.0000000000002670","volume":"53","author":"S Bhasin","year":"2021","unstructured":"Bhasin S, Hatfield DL, Hoffman JR et al (2021) Anabolic-androgenic steroid use in sports, health, and society. Med Sci Sports Exerc 53:1778\u20131794. https:\/\/doi.org\/10.1249\/MSS.0000000000002670","journal-title":"Med Sci Sports Exerc"},{"key":"2767_CR79","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1002\/psc.2969","volume":"23","author":"C Nagai-Okatani","year":"2017","unstructured":"Nagai-Okatani C, Kangawa K, Minamino N (2017) Three molecular forms of atrial natriuretic peptides: quantitative analysis and biological characterization. J Pept Sci 23:486\u2013495. https:\/\/doi.org\/10.1002\/psc.2969","journal-title":"J Pept Sci"},{"key":"2767_CR80","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.peptides.2018.05.012","volume":"111","author":"Y Nakagawa","year":"2019","unstructured":"Nakagawa Y, Nishikimi T, Kuwahara K (2019) Atrial and brain natriuretic peptides: hormones secreted from the heart. Peptides 111:18\u201325. https:\/\/doi.org\/10.1016\/j.peptides.2018.05.012","journal-title":"Peptides"},{"key":"2767_CR81","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.biochi.2015.05.017","volume":"124","author":"M Cou\u00e9","year":"2016","unstructured":"Cou\u00e9 M, Moro C (2016) Natriuretic peptide control of energy balance and glucose homeostasis. Biochimie 124:84\u201391. https:\/\/doi.org\/10.1016\/j.biochi.2015.05.017","journal-title":"Biochimie"},{"key":"2767_CR82","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.cca.2015.07.004","volume":"448","author":"TG Yandle","year":"2015","unstructured":"Yandle TG, Richards AM (2015) B-type natriuretic peptide circulating forms: analytical and bioactivity issues. Clin Chim Acta 448:195\u2013205. https:\/\/doi.org\/10.1016\/j.cca.2015.07.004","journal-title":"Clin Chim Acta"},{"key":"2767_CR83","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1172\/JCI115146","volume":"87","author":"M Mukoyama","year":"1991","unstructured":"Mukoyama M, Nakao K, Hosoda K et al (1991) Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 87:1402\u20131412. https:\/\/doi.org\/10.1172\/JCI115146","journal-title":"J Clin Invest"},{"key":"2767_CR84","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1056\/NEJMoa020233","volume":"347","author":"AS Maisel","year":"2002","unstructured":"Maisel AS, Krishnaswamy P, Nowak RM et al (2002) Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347:161\u2013167. https:\/\/doi.org\/10.1056\/NEJMoa020233","journal-title":"N Engl J Med"},{"key":"2767_CR85","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.jacc.2011.05.042","volume":"58","author":"J Polak","year":"2011","unstructured":"Polak J, Kotrc M, Wedellova Z et al (2011) Lipolytic effects of B-type natriuretic peptide 1-32 in adipose tissue of heart failure patients compared with healthy controls. J Am Coll Cardiol 58:1119\u20131125. https:\/\/doi.org\/10.1016\/j.jacc.2011.05.042","journal-title":"J Am Coll Cardiol"},{"key":"2767_CR86","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1007\/s00125-011-2392-1","volume":"55","author":"BB Heinisch","year":"2012","unstructured":"Heinisch BB, Vila G, Resl M et al (2012) B-type natriuretic peptide (BNP) affects the initial response to intravenous glucose: a randomised placebo-controlled cross-over study in healthy men. Diabetologia 55:1400\u20131405. https:\/\/doi.org\/10.1007\/s00125-011-2392-1","journal-title":"Diabetologia"},{"key":"2767_CR87","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.peptides.2018.11.003","volume":"112","author":"ED Bartels","year":"2019","unstructured":"Bartels ED, Guo S, Kousholt BS et al (2019) High doses of ANP and BNP exacerbate lipolysis in humans and the lipolytic effect of BNP is associated with cardiac triglyceride content in pigs. Peptides 112:43\u201347. https:\/\/doi.org\/10.1016\/j.peptides.2018.11.003","journal-title":"Peptides"},{"key":"2767_CR88","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.peptides.2017.10.007","volume":"99","author":"MO Wilson","year":"2018","unstructured":"Wilson MO, Barrell GK, Prickett TCR, Espiner EA (2018) Molecular forms of C-type natriuretic peptide in cerebrospinal fluid and plasma reflect differential processing in brain and pituitary tissues. Peptides 99:223\u2013230. https:\/\/doi.org\/10.1016\/j.peptides.2017.10.007","journal-title":"Peptides"},{"key":"2767_CR89","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.peptides.2012.12.010","volume":"40","author":"S Del Ry","year":"2013","unstructured":"Del Ry S (2013) C-type natriuretic peptide: a new cardiac mediator. Peptides 40:93\u201398. https:\/\/doi.org\/10.1016\/j.peptides.2012.12.010","journal-title":"Peptides"},{"key":"2767_CR90","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20092281","volume":"20","author":"AJ Moyes","year":"2019","unstructured":"Moyes AJ, Hobbs AJ (2019) C-type natriuretic peptide: a multifaceted paracrine regulator in the heart and vasculature. Int J Mol Sci 20:2281. https:\/\/doi.org\/10.3390\/ijms20092281","journal-title":"Int J Mol Sci"},{"key":"2767_CR91","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.jacc.2004.10.067","volume":"45","author":"T Soeki","year":"2005","unstructured":"Soeki T, Kishimoto I, Okumura H et al (2005) C-type natriuretic peptide, a novel antifibrotic and antihypertrophic agent, prevents cardiac remodeling after myocardial infarction. J Am Coll Cardiol 45:608\u2013616. https:\/\/doi.org\/10.1016\/j.jacc.2004.10.067","journal-title":"J Am Coll Cardiol"},{"key":"2767_CR92","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1111\/j.1742-4658.2011.08082.x","volume":"278","author":"LR Potter","year":"2011","unstructured":"Potter LR (2011) Natriuretic peptide metabolism, clearance and degradation. FEBS J 278:1808\u20131817. https:\/\/doi.org\/10.1111\/j.1742-4658.2011.08082.x","journal-title":"FEBS J"},{"key":"2767_CR93","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1093\/eurheartj\/ehz093","volume":"41","author":"AJ Moyes","year":"2020","unstructured":"Moyes AJ, Chu SM, Aubdool AA et al (2020) C-type natriuretic peptide co-ordinates cardiac structure and function. Eur Heart J 41:1006\u20131020. https:\/\/doi.org\/10.1093\/eurheartj\/ehz093","journal-title":"Eur Heart J"},{"key":"2767_CR94","doi-asserted-by":"publisher","DOI":"10.1258\/cvd.2012.012003","volume":"1","author":"HK Wong","year":"2012","unstructured":"Wong HK, Cheung TT, Cheung BMY (2012) Adrenomedullin and cardiovascular diseases. JRSM Cardiovasc Dis 1:cvd.2012.012003. https:\/\/doi.org\/10.1258\/cvd.2012.012003","journal-title":"JRSM Cardiovasc Dis"},{"key":"2767_CR95","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1002\/ejhf.1437","volume":"21","author":"JM Ter Maaten","year":"2019","unstructured":"Ter Maaten JM, Kremer D, Demissei BG et al (2019) Bio-adrenomedullin as a marker of congestion in patients with new-onset and worsening heart failure. Eur J Heart Fail 21:732\u2013743. https:\/\/doi.org\/10.1002\/ejhf.1437","journal-title":"Eur J Heart Fail"},{"key":"2767_CR96","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1002\/ejhf.1366","volume":"21","author":"AA Voors","year":"2019","unstructured":"Voors AA, Kremer D, Geven C et al (2019) Adrenomedullin in heart failure: pathophysiology and therapeutic application. Eur J Heart Fail 21:163\u2013171. https:\/\/doi.org\/10.1002\/ejhf.1366","journal-title":"Eur J Heart Fail"},{"key":"2767_CR97","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/s0002-8703(96)90185-4","volume":"131","author":"K Kobayashi","year":"1996","unstructured":"Kobayashi K, Kitamura K, Etoh T et al (1996) Increased plasma adrenomedullin levels in chronic congestive heart failure. Am Heart J 131:994\u2013998. https:\/\/doi.org\/10.1016\/s0002-8703(96)90185-4","journal-title":"Am Heart J"},{"key":"2767_CR98","doi-asserted-by":"publisher","first-page":"4512","DOI":"10.3390\/jcm10194512","volume":"10","author":"K Takagi","year":"2021","unstructured":"Takagi K, Levy B, Kimmoun A et al (2021) Elevated plasma bioactive adrenomedullin and mortality in cardiogenic shock: results from the OptimaCC trial. J Clin Med 10:4512. https:\/\/doi.org\/10.3390\/jcm10194512","journal-title":"J Clin Med"},{"key":"2767_CR99","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.938112","volume":"28","author":"J Rozwadowski","year":"2022","unstructured":"Rozwadowski J, Borodzicz-Ja\u017cd\u017cyk S, Czarzasta K, Cudnoch-J\u0119drzejewska A (2022) A review of the roles of apelin and ELABELA peptide ligands in cardiovascular disease, including heart failure and hypertension. Med Sci Monit 28:e938112. https:\/\/doi.org\/10.12659\/MSM.938112","journal-title":"Med Sci Monit"},{"key":"2767_CR100","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1007\/s10741-020-09957-5","volume":"26","author":"Z Ma","year":"2021","unstructured":"Ma Z, Song J-J, Martin S et al (2021) The Elabela-APJ axis: a promising therapeutic target for heart failure. Heart Fail Rev 26:1249\u20131258. https:\/\/doi.org\/10.1007\/s10741-020-09957-5","journal-title":"Heart Fail Rev"},{"key":"2767_CR101","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.961805","volume":"13","author":"C Liu","year":"2022","unstructured":"Liu C, Yang M, Zhang D et al (2022) Clinical cancer immunotherapy: current progress and prospects. Front Immunol 13:961805. https:\/\/doi.org\/10.3389\/fimmu.2022.961805","journal-title":"Front Immunol"},{"key":"2767_CR102","doi-asserted-by":"publisher","first-page":"11841","DOI":"10.1038\/s41598-019-48356-1","volume":"9","author":"H Sunaga","year":"2019","unstructured":"Sunaga H, Koitabashi N, Iso T et al (2019) Activation of cardiac AMPK-FGF21 feed-forward loop in acute myocardial infarction: role of adrenergic overdrive and lipolysis byproducts. Sci Rep 9:11841. https:\/\/doi.org\/10.1038\/s41598-019-48356-1","journal-title":"Sci Rep"},{"key":"2767_CR103","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.121.008910","volume":"15","author":"S Sommakia","year":"2022","unstructured":"Sommakia S, Almaw NH, Lee SH et al (2022) FGF21 (Fibroblast Growth Factor 21) defines a potential cardiohepatic signaling circuit in end-stage heart failure. Circ Heart Fail 15:e008910. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.121.008910","journal-title":"Circ Heart Fail"},{"key":"2767_CR104","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1038\/ncomms3019","volume":"4","author":"A Planavila","year":"2013","unstructured":"Planavila A, Redondo I, Hondares E et al (2013) Fibroblast growth factor 21 protects against cardiac hypertrophy in mice. Nat Commun 4:2019. https:\/\/doi.org\/10.1038\/ncomms3019","journal-title":"Nat Commun"},{"key":"2767_CR105","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1530\/EJE-12-0357","volume":"167","author":"P Iglesias","year":"2012","unstructured":"Iglesias P, Selgas R, Romero S, D\u00edez JJ (2012) Biological role, clinical significance, and therapeutic possibilities of the recently discovered metabolic hormone fibroblastic growth factor 21. Eur J Endocrinol 167:301\u2013309. https:\/\/doi.org\/10.1530\/EJE-12-0357","journal-title":"Eur J Endocrinol"},{"key":"2767_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2023.155535","volume":"143","author":"W Tucker","year":"2023","unstructured":"Tucker W, McClelland RL, Allison MA et al (2023) The association of circulating fibroblast growth factor 21 levels with incident heart failure: the Multi-Ethnic Study of Atherosclerosis. Metabolism 143:155535. https:\/\/doi.org\/10.1016\/j.metabol.2023.155535","journal-title":"Metabolism"},{"key":"2767_CR107","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1080\/10408363.2019.1678565","volume":"57","author":"M Arkoumani","year":"2020","unstructured":"Arkoumani M, Papadopoulou-Marketou N, Nicolaides NC et al (2020) The clinical impact of growth differentiation factor-15 in heart disease: a 2019 update. Crit Rev Clin Lab Sci 57:114\u2013125. https:\/\/doi.org\/10.1080\/10408363.2019.1678565","journal-title":"Crit Rev Clin Lab Sci"},{"key":"2767_CR108","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22168889","volume":"22","author":"L Rochette","year":"2021","unstructured":"Rochette L, Dogon G, Zeller M et al (2021) GDF15 and cardiac cells: current concepts and new insights. Int J Mol Sci 22:8889. https:\/\/doi.org\/10.3390\/ijms22168889","journal-title":"Int J Mol Sci"},{"key":"2767_CR109","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ejim.2021.02.011","volume":"88","author":"S Nopp","year":"2021","unstructured":"Nopp S, K\u00f6nigsbr\u00fcgge O, Kraemmer D et al (2021) Growth differentiation factor-15 predicts major adverse cardiac events and all-cause mortality in patients with atrial fibrillation. Eur J Intern Med 88:35\u201342. https:\/\/doi.org\/10.1016\/j.ejim.2021.02.011","journal-title":"Eur J Intern Med"},{"key":"2767_CR110","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1093\/eurheartj\/ehac577","volume":"44","author":"ET Kato","year":"2023","unstructured":"Kato ET, Morrow DA, Guo J et al (2023) Growth differentiation factor 15 and cardiovascular risk: individual patient meta-analysis. Eur Heart J 44:293\u2013300. https:\/\/doi.org\/10.1093\/eurheartj\/ehac577","journal-title":"Eur Heart J"},{"key":"2767_CR111","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e35916","volume":"10","author":"A Javaheri","year":"2024","unstructured":"Javaheri A, Ozcan M, Moubarak L et al (2024) Association between growth differentiation factor-15 and adverse outcomes among patients with heart failure: a systematic literature review. Heliyon 10:e35916. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e35916","journal-title":"Heliyon"},{"key":"2767_CR112","doi-asserted-by":"publisher","first-page":"66","DOI":"10.7150\/ijbs.73936","volume":"19","author":"H Tan","year":"2023","unstructured":"Tan H, Yue T, Chen Z et al (2023) Targeting FGF21 in cardiovascular and metabolic diseases: from mechanism to medicine. Int J Biol Sci 19:66\u201388. https:\/\/doi.org\/10.7150\/ijbs.73936","journal-title":"Int J Biol Sci"},{"key":"2767_CR113","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1093\/cvr\/cvae214","volume":"120","author":"M Takaoka","year":"2024","unstructured":"Takaoka M, Tadross JA, Al-Hadithi ABAK et al (2024) GDF15 antagonism limits severe heart failure and prevents cardiac cachexia. Cardiovasc Res 120:2249\u20132260. https:\/\/doi.org\/10.1093\/cvr\/cvae214","journal-title":"Cardiovasc Res"},{"key":"2767_CR114","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1172\/JCI30634","volume":"117","author":"S Sanada","year":"2007","unstructured":"Sanada S, Hakuno D, Higgins LJ et al (2007) IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 117:1538\u20131549. https:\/\/doi.org\/10.1172\/JCI30634","journal-title":"J Clin Invest"},{"key":"2767_CR115","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12093136","volume":"12","author":"M Dudek","year":"2023","unstructured":"Dudek M, Ka\u0142u\u017cna-Oleksy M, Migaj J et al (2023) sST2 and heart failure-clinical utility and prognosis. J Clin Med 12:3136. https:\/\/doi.org\/10.3390\/jcm12093136","journal-title":"J Clin Med"},{"key":"2767_CR116","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1161\/CIRCRESAHA.116.309398","volume":"120","author":"M Appari","year":"2017","unstructured":"Appari M, Breitbart A, Brandes F et al (2017) C1q-TNF-Related Protein-9 Promotes Cardiac Hypertrophy and Failure. Circ Res 120:66\u201377. https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.309398","journal-title":"Circ Res"},{"key":"2767_CR117","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/s41419-018-0726-3","volume":"9","author":"D Zhao","year":"2018","unstructured":"Zhao D, Feng P, Sun Y et al (2018) Cardiac-derived CTRP9 protects against myocardial ischemia\/reperfusion injury via calreticulin-dependent inhibition of apoptosis. Cell Death Dis 9:723. https:\/\/doi.org\/10.1038\/s41419-018-0726-3","journal-title":"Cell Death Dis"},{"key":"2767_CR118","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3390\/cells12030443","volume":"12","author":"R Haustein","year":"2023","unstructured":"Haustein R, Trogisch FA, Keles M et al (2023) C1q and tumor necrosis factor related protein 9 protects from diabetic cardiomyopathy by alleviating cardiac insulin resistance and inflammation. Cells 12:443. https:\/\/doi.org\/10.3390\/cells12030443","journal-title":"Cells"},{"key":"2767_CR119","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.18488","volume":"12","author":"Z Zhu","year":"2024","unstructured":"Zhu Z, Niu Q, Tang S, Jiang Y (2024) Association between circulating CTRP9 levels and coronary artery disease: a systematic review and meta-analysis. PeerJ 12:e18488. https:\/\/doi.org\/10.7717\/peerj.18488","journal-title":"PeerJ"},{"key":"2767_CR120","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1001\/jama.2023.2020","volume":"329","author":"MM Redfield","year":"2023","unstructured":"Redfield MM, Borlaug BA (2023) Heart failure with preserved ejection fraction: a review. JAMA 329:827\u2013838. https:\/\/doi.org\/10.1001\/jama.2023.2020","journal-title":"JAMA"},{"key":"2767_CR121","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1016\/j.jacc.2019.08.1039","volume":"74","author":"A Aimo","year":"2019","unstructured":"Aimo A, Januzzi JL, Bayes-Genis A et al (2019) Clinical and Prognostic Significance of sST2 in Heart Failure: JACC Review Topic of the Week. J Am Coll Cardiol 74:2193\u20132203. https:\/\/doi.org\/10.1016\/j.jacc.2019.08.1039","journal-title":"J Am Coll Cardiol"},{"key":"2767_CR122","doi-asserted-by":"publisher","first-page":"e1054","DOI":"10.1161\/CIR.0000000000000490","volume":"135","author":"SL Chow","year":"2017","unstructured":"Chow SL, Maisel AS, Anand I et al (2017) Role of biomarkers for the prevention, assessment, and management of heart failure: a scientific statement from the American Heart Association. Circulation 135:e1054\u2013e1091. https:\/\/doi.org\/10.1161\/CIR.0000000000000490","journal-title":"Circulation"},{"key":"2767_CR123","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1016\/j.jacc.2018.08.2165","volume":"72","author":"M Emdin","year":"2018","unstructured":"Emdin M, Aimo A, Vergaro G et al (2018) sST2 predicts outcome in chronic\u00a0heart\u00a0failure beyond NT-proBNP and high-sensitivity troponin T. J Am Coll Cardiol 72:2309\u20132320. https:\/\/doi.org\/10.1016\/j.jacc.2018.08.2165","journal-title":"J Am Coll Cardiol"},{"key":"2767_CR124","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26030986","volume":"26","author":"M Cort\u00e9s","year":"2025","unstructured":"Cort\u00e9s M, Lumpuy-Castillo J, Garc\u00eda-Talavera CS et al (2025) New biomarkers in the prognostic assessment of acute heart failure with reduced ejection fraction: beyond natriuretic peptides. Int J Mol Sci 26:986. https:\/\/doi.org\/10.3390\/ijms26030986","journal-title":"Int J Mol Sci"},{"key":"2767_CR125","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1002\/ejhf.2346","volume":"23","author":"WC Meijers","year":"2021","unstructured":"Meijers WC, Bayes-Genis A, Mebazaa A et al (2021) Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of Cardiology (ESC). Eur J Heart Fail 23:1610\u20131632. https:\/\/doi.org\/10.1002\/ejhf.2346","journal-title":"Eur J Heart Fail"},{"key":"2767_CR126","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s10741-021-10105-w","volume":"27","author":"V Castiglione","year":"2022","unstructured":"Castiglione V, Aimo A, Vergaro G et al (2022) Biomarkers for the diagnosis and management of heart failure. Heart Fail Rev 27:625\u2013643. https:\/\/doi.org\/10.1007\/s10741-021-10105-w","journal-title":"Heart Fail Rev"},{"key":"2767_CR127","doi-asserted-by":"publisher","DOI":"10.1016\/j.bios.2024.116090","volume":"255","author":"T Dong","year":"2024","unstructured":"Dong T, Zhu W, Yang Z et al (2024) Advances in heart failure monitoring: biosensors targeting molecular markers in peripheral bio-fluids. Biosens Bioelectron 255:116090. https:\/\/doi.org\/10.1016\/j.bios.2024.116090","journal-title":"Biosens Bioelectron"},{"key":"2767_CR128","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1002\/ejhf.1690","volume":"22","author":"A Bayes-Genis","year":"2020","unstructured":"Bayes-Genis A, Emdin M, N\u00fa\u00f1ez J (2020) Biomarker-guided management in acute heart failure: is there light at the end of the tunnel? Eur J Heart Fail 22:276\u2013278. https:\/\/doi.org\/10.1002\/ejhf.1690","journal-title":"Eur J Heart Fail"},{"key":"2767_CR129","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.122.009526","volume":"16","author":"MT G\u00fcrg\u00f6ze","year":"2023","unstructured":"G\u00fcrg\u00f6ze MT, van Vark LC, Baart SJ et al (2023) Multimarker analysis of serially measured GDF-15, NT-proBNP, ST2, GAL-3, cTnI, creatinine, and prognosis in acute heart failure. Circ Heart Fail 16:e009526. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.122.009526","journal-title":"Circ Heart Fail"},{"key":"2767_CR130","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.cardfail.2023.02.009","volume":"29","author":"H Tsutsui","year":"2023","unstructured":"Tsutsui H, Albert NM, Coats AJS et al (2023) Natriuretic peptides: role in the diagnosis and management of heart failure: a scientific statement from the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society. J Card Fail 29:787\u2013804. https:\/\/doi.org\/10.1016\/j.cardfail.2023.02.009","journal-title":"J Card Fail"},{"key":"2767_CR131","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1016\/j.jacc.2021.12.011","volume":"79","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D et al (2022) 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 79:1757\u20131780. https:\/\/doi.org\/10.1016\/j.jacc.2021.12.011","journal-title":"J Am Coll Cardiol"},{"key":"2767_CR132","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.amjcard.2023.09.060","volume":"208","author":"P Stojadinovic","year":"2023","unstructured":"Stojadinovic P, Wichterle D, Fukunaga M et al (2023) Acute effect of atrial fibrillation on circulating natriuretic peptides: the influence of heart rate, rhythm irregularity, and left atrial pressure overload. Am J Cardiol 208:156\u2013163. https:\/\/doi.org\/10.1016\/j.amjcard.2023.09.060","journal-title":"Am J Cardiol"},{"key":"2767_CR133","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1161\/CIRCULATIONAHA.114.013748","volume":"131","author":"M Packer","year":"2015","unstructured":"Packer M, McMurray JJV, Desai AS et al (2015) Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 131:54\u201361. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.013748","journal-title":"Circulation"},{"key":"2767_CR134","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1001\/jama.2019.12821","volume":"322","author":"JL Januzzi","year":"2019","unstructured":"Januzzi JL, Prescott MF, Butler J et al (2019) Association of change in N-terminal pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction. JAMA 322:1085\u20131095. https:\/\/doi.org\/10.1001\/jama.2019.12821","journal-title":"JAMA"},{"key":"2767_CR135","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1016\/j.jacc.2020.08.031","volume":"76","author":"M Emdin","year":"2020","unstructured":"Emdin M, Aimo A, Castiglione V et al (2020) Targeting cyclic guanosine monophosphate to treat heart failure: JACC review topic of the week. J Am Coll Cardiol 76:1795\u20131807. https:\/\/doi.org\/10.1016\/j.jacc.2020.08.031","journal-title":"J Am Coll Cardiol"},{"key":"2767_CR136","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1097\/CM9.0000000000001890","volume":"134","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Liu D, Long X-X et al (2021) The role of FGF21 in the pathogenesis of cardiovascular disease. Chin Med J (Engl) 134:2931\u20132943. https:\/\/doi.org\/10.1097\/CM9.0000000000001890","journal-title":"Chin Med J (Engl)"},{"key":"2767_CR137","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s00109-025-02565-6","volume":"103","author":"S Zhao","year":"2025","unstructured":"Zhao S, Huang D, Huang R et al (2025) Unveiling the roles of CTRP family in cardiac remodeling. J Mol Med (Berl) 103:935\u2013950. https:\/\/doi.org\/10.1007\/s00109-025-02565-6","journal-title":"J Mol Med (Berl)"},{"key":"2767_CR138","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.cytogfr.2023.06.003","volume":"71\u201372","author":"PV Thanikachalam","year":"2023","unstructured":"Thanikachalam PV, Ramamurthy S, Mallapu P et al (2023) Modulation of IL-33\/ST2 signaling as a potential new therapeutic target for cardiovascular diseases. Cytokine Growth Factor Rev 71\u201372:94\u2013104. https:\/\/doi.org\/10.1016\/j.cytogfr.2023.06.003","journal-title":"Cytokine Growth Factor Rev"},{"key":"2767_CR139","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1161\/HYPERTENSIONAHA.107.097634","volume":"50","author":"D Conen","year":"2007","unstructured":"Conen D, Glynn RJ, Buring JE et al (2007) Natriuretic peptide precursor a gene polymorphisms and risk of blood pressure progression and incident hypertension. Hypertension 50:1114\u20131119. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.107.097634","journal-title":"Hypertension"},{"key":"2767_CR140","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1373\/clinchem.2008.120832","volume":"55","author":"C Vassalle","year":"2009","unstructured":"Vassalle C, Andreassi MG (2009) Genetic polymorphisms of the natriuretic peptide system in the pathogenesis of cardiovascular disease: what lies on the horizon? Clin Chem 55:878\u2013887. https:\/\/doi.org\/10.1373\/clinchem.2008.120832","journal-title":"Clin Chem"},{"key":"2767_CR141","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/ng.328","volume":"41","author":"C Newton-Cheh","year":"2009","unstructured":"Newton-Cheh C, Larson MG, Vasan RS et al (2009) Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nat Genet 41:348\u2013353. https:\/\/doi.org\/10.1038\/ng.328","journal-title":"Nat Genet"},{"key":"2767_CR142","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.jacc.2011.05.011","volume":"58","author":"V Cannone","year":"2011","unstructured":"Cannone V, Boerrigter G, Cataliotti A et al (2011) A genetic variant of the atrial natriuretic peptide gene is associated with cardiometabolic protection in the general community. J Am Coll Cardiol 58:629\u2013636. https:\/\/doi.org\/10.1016\/j.jacc.2011.05.011","journal-title":"J Am Coll Cardiol"},{"key":"2767_CR143","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1126\/science.aaz1776","volume":"369","author":"GTEx Consortium","year":"2020","unstructured":"GTEx Consortium (2020) The GTEx consortium atlas of genetic regulatory effects across human tissues. Science 369:1318\u20131330. https:\/\/doi.org\/10.1126\/science.aaz1776","journal-title":"Science"},{"key":"2767_CR144","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1016\/j.ajhg.2023.08.009","volume":"110","author":"S van Duijvenboden","year":"2023","unstructured":"van Duijvenboden S, Ram\u00edrez J, Young WJ et al (2023) Integration of genetic fine-mapping and multi-omics data reveals candidate effector genes for hypertension. Am J Hum Genet 110:1718\u20131734. https:\/\/doi.org\/10.1016\/j.ajhg.2023.08.009","journal-title":"Am J Hum Genet"},{"key":"2767_CR145","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1161\/HYPERTENSIONAHA.123.22538","volume":"81","author":"O Yaacov","year":"2024","unstructured":"Yaacov O, Mathiyalagan P, Berk-Rauch HE et al (2024) Identification of the molecular components of enhancer-mediated gene expression variation in multiple tissues regulating blood pressure. Hypertension 81:1500\u20131510. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.123.22538","journal-title":"Hypertension"},{"key":"2767_CR146","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1161\/CIRCRESAHA.118.313161","volume":"122","author":"E Lau","year":"2018","unstructured":"Lau E, Wu JC (2018) Omics, big data, and precision medicine in cardiovascular sciences. Circ Res 122:1165\u20131168. https:\/\/doi.org\/10.1161\/CIRCRESAHA.118.313161","journal-title":"Circ Res"},{"key":"2767_CR147","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13825","volume":"25","author":"A Ajoolabady","year":"2024","unstructured":"Ajoolabady A, Pratico D, Dunn WB et al (2024) Metabolomics: implication in cardiovascular research and diseases. Obes Rev 25:e13825. https:\/\/doi.org\/10.1111\/obr.13825","journal-title":"Obes Rev"},{"key":"2767_CR148","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.70878","volume":"8","author":"A Nazir","year":"2025","unstructured":"Nazir A, Nazir A, Afzaal U et al (2025) Advancements in biomarkers for early detection and risk stratification of cardiovascular diseases-a literature review. Health Sci Rep 8:e70878. https:\/\/doi.org\/10.1002\/hsr2.70878","journal-title":"Health Sci Rep"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-025-02767-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-025-02767-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-025-02767-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T12:47:34Z","timestamp":1775479654000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-025-02767-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":148,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["2767"],"URL":"https:\/\/doi.org\/10.1007\/s40618-025-02767-2","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,3]]},"assertion":[{"value":"22 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of interest related to this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}